The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Interim safety and efficacy of BP1001 in a phase II acute myeloid leukemia (AML) study.
 
Maro Ohanian
Consulting or Advisory Role - Bio-Path Holdings, Inc; Charter Oak Field Services; Curio Science; Dedham Group; Reckner Healthcare
Patents, Royalties, Other Intellectual Property - Pleco Therapeutics
 
Maher Abdul-Hay
No Relationships to Disclose
 
Tara L. Lin
Consulting or Advisory Role - SERVIER
Research Funding - Aptevo Therapeutics (Inst); Astellas Pharma (Inst); Bio-Path Holdings, Inc (Inst); Cardiff Oncology (Inst); Celyad (Inst); CicloMed (Inst); Cleave Biosciences (Inst); Jazz Pharmaceuticals (Inst); Kura Oncology (Inst)
 
Ellen K. Ritchie
Consulting or Advisory Role - bristol myers squibb; Celgene; Incyte; Novartis; Pfizer
Speakers' Bureau - Celgene; Incyte
Research Funding - Astellas Pharma (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Vamsi Kota
Consulting or Advisory Role - Novartis; Pfizer
 
Miranda Lim
No Relationships to Disclose
 
Sherry Pierce
No Relationships to Disclose
 
Michael Hickey
Employment - Bio-Path Holdings
Leadership - Bio-Path Holdings
Stock and Other Ownership Interests - Bio-Path Holdings
 
Ana Tari Ashizawa
Employment - Bio-Path Holdings
Leadership - Bio-Path Holdings
Stock and Other Ownership Interests - Bio-Path Holdings
Patents, Royalties, Other Intellectual Property - Bio-Path Holdings, Inc
 
Hagop M. Kantarjian
Honoraria - Abbvie; Amgen; Ascentage Pharma Group; Astellas Pharma; AstraZeneca/MedImmune; Daiichih-Sankyo (Inst); Immunogen (Inst); Ipsen; Jazz Pharmaceuticals (Inst); KAHR Medical; Novartis; Pfizer; Precision Biosciences; Shenzhen Target Rx; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie
Research Funding - Abbvie (Inst); Amgen (Inst); Ascentage Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Lilly (Inst); Immunogen (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst)
 
Jorge E. Cortes
Consulting or Advisory Role - Bio-Path Holdings, Inc; Gilead Sciences; Novartis; Pfizer; Rigel; Sun Pharma; Takeda; Terns Pharmaceuticals
Research Funding - Abbvie/Genentech (Inst); Actuate Therapeutics (Inst); Bio-Path Holdings, Inc (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Sellas Life Sciences (Inst); Sun Pharma (Inst); Takeda (Inst)
 
Gail J. Roboz
Consulting or Advisory Role - Abbvie; Actinium Pharmaceuticals; Agios; Amgen; Astellas Pharma; Astex Pharmaceuticals; Bayer; Bristol-Myers Squibb; Celgene; Celltrion; Daiichi Sankyo; Genentech/Roche; GlaxoSmithKline; Helsinn Therapeutics; Janssen; Jasper Therapeutics; Jazz Pharmaceuticals; MedImmune; MEI Pharma; Mesoblast; Novartis; Otsuka; Pfizer; Roche; Sandoz; Takeda
Research Funding - Abbvie (Inst); Agios (Inst); Amphivena Therapeutics (Inst); Astex Pharmaceuticals (Inst); Celgene (Inst); Cellectis (Inst); CTI (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); MEI Pharma (Inst); Moffitt Cancer Center (Inst); Novartis (Inst); Onconova Therapeutics (Inst); Pfizer (Inst); Sunesis Pharmaceuticals (Inst); Tensha Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; Agios; Amgen; Amphivena Therapeutics; Array BioPharma; Astex Pharmaceuticals; Bayer; Celgene; Celltrion; Clovis Oncology; Eisai; Genentech/Roche; Janssen; Jazz Pharmaceuticals; Novartis; Pfizer; Sandoz; Sunesis Pharmaceuticals